Literature DB >> 3518432

Efficacy and safety of diclofenac sodium in rheumatoid arthritis. Experience in the United States.

J R Caldwell.   

Abstract

Diclofenac sodium is a nonsteroidal, anti-inflammatory drug that has been studied in the United States for the treatment of rheumatoid arthritis in 681 patients, 468 of whom were enrolled in five multicenter, double-blind parallel controlled investigations. Results of these trials indicate that 150 mg daily of diclofenac is more effective than placebo and as effective as 2.4 g daily of ibuprofen or 3.6 g daily of aspirin. Moreover, the safety profile of diclofenac proved to be better than that of aspirin and similar to that of ibuprofen.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3518432     DOI: 10.1016/0002-9343(86)90079-3

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  5 in total

1.  Diclofenac delays healing of gastroduodenal mucosal lesions. Double-blind, placebo-controlled endoscopic study in healthy volunteers.

Authors:  P Stadler; D Armstrong; D Margalith; E Saraga; M Stolte; P Lualdi; G Mautone; A L Blum
Journal:  Dig Dis Sci       Date:  1991-05       Impact factor: 3.199

2.  Tablet formulation study of spray-dried sodium diclofenac enteric-coated microcapsules.

Authors:  S Y Lin; Y H Kao
Journal:  Pharm Res       Date:  1991-07       Impact factor: 4.200

Review 3.  Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

4.  Single intramuscular injection of diclofenac sodium in febrile pediatric patients.

Authors:  Jun Yeol Lee; Jun Hwi Cho; Myoung Cheol Shin; Taek Geun Ohk; Hui Young Lee; Chan Woo Park
Journal:  Indian J Pharmacol       Date:  2015 May-Jun       Impact factor: 1.200

Review 5.  Advances in NSAID development: evolution of diclofenac products using pharmaceutical technology.

Authors:  Roy Altman; Bill Bosch; Kay Brune; Paola Patrignani; Clarence Young
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.